Extensive research is being conducted in search of neuroprotective agents for possible use in the acute phase of stroke and agents that can be used for neurorepair following stroke. Sovateltide takes a novel approach by stimulation of ETB receptors to treat cerebral ischemic stroke through neuroprotective and neuro-repair pathways. Sovateltide has been effective in animal models of cerebral ischemic stroke. Clinical phase I, II, and III results indicate that sovateltide is a highly effective drug candidate for treating cerebral ischemic stroke. Phase II and Phase III studies in ischemic strokes demonstrated significant efficacy in improving the National Institutes of Health Stroke Scale (NIHSS), Modified Rankin Scale (mRS), and Barthel Index (BI) domains, with a favorable safety profile.
RESPECT-ETB is a global phase III clinical study to evaluate the safety and efficacy of sovateltide therapy along with the standard of care in patients of acute ischemic stroke.
